收费全文 | 7489篇 |
免费 | 557篇 |
国内免费 | 34篇 |
耳鼻咽喉 | 211篇 |
儿科学 | 168篇 |
妇产科学 | 76篇 |
基础医学 | 1175篇 |
口腔科学 | 161篇 |
临床医学 | 517篇 |
内科学 | 1355篇 |
皮肤病学 | 54篇 |
神经病学 | 481篇 |
特种医学 | 247篇 |
外国民族医学 | 1篇 |
外科学 | 1537篇 |
综合类 | 60篇 |
一般理论 | 6篇 |
预防医学 | 484篇 |
眼科学 | 710篇 |
药学 | 324篇 |
中国医学 | 5篇 |
肿瘤学 | 508篇 |
2023年 | 89篇 |
2022年 | 44篇 |
2021年 | 228篇 |
2020年 | 156篇 |
2019年 | 242篇 |
2018年 | 240篇 |
2017年 | 183篇 |
2016年 | 201篇 |
2015年 | 189篇 |
2014年 | 291篇 |
2013年 | 331篇 |
2012年 | 486篇 |
2011年 | 443篇 |
2010年 | 283篇 |
2009年 | 250篇 |
2008年 | 407篇 |
2007年 | 408篇 |
2006年 | 360篇 |
2005年 | 361篇 |
2004年 | 324篇 |
2003年 | 304篇 |
2002年 | 316篇 |
2001年 | 157篇 |
2000年 | 149篇 |
1999年 | 127篇 |
1998年 | 68篇 |
1997年 | 41篇 |
1996年 | 49篇 |
1995年 | 55篇 |
1994年 | 47篇 |
1993年 | 34篇 |
1992年 | 71篇 |
1991年 | 72篇 |
1990年 | 60篇 |
1989年 | 52篇 |
1988年 | 62篇 |
1987年 | 53篇 |
1986年 | 49篇 |
1985年 | 50篇 |
1984年 | 32篇 |
1979年 | 29篇 |
1933年 | 31篇 |
1930年 | 34篇 |
1928年 | 33篇 |
1927年 | 33篇 |
1926年 | 34篇 |
1925年 | 41篇 |
1924年 | 37篇 |
1923年 | 29篇 |
1922年 | 30篇 |
Background
Glutamate plays a key role for post-ischaemic recovery of myocardial metabolism. According to post hoc analyses of the two GLUTAMICS trials, patients without diabetes benefit from glutamate with less myocardial dysfunction after coronary artery bypass surgery (CABG). Copeptin reflects activation of the Arginine Vasopressin system and is a reliable marker of heart failure but available studies in cardiac surgery are limited. We investigated whether glutamate infusion is associated with reduced postoperative rises of plasma Copeptin (p-Copeptin) after CABG.Methods
A prespecified randomised double-blind substudy of GLUTAMICS II. Patients had left ventricular ejection fraction ≤0.30 or EuroSCORE II ≥3.0 and underwent CABG ± valve procedure. Intravenous infusion of 0.125 M L-glutamic acid or saline at 1.65 mL/kg/h was commenced 10–20 min before the release of the aortic cross-clamp and then continued for another 150 min P-Copeptin was measured preoperatively and postoperatively on day one (POD1) and day three. The primary endpoint was an increase in p-Copeptin from the preoperative level to POD1. Postoperative stroke ≤24 h and mortality ≤30 days were safety outcomes.Results
We included 181 patients of whom 48% had diabetes. The incidence of postoperative mortality ≤30 days (0% vs. 2.1%; p = .50) and stroke ≤24 h (0% vs. 3.2%; p = .25) did not differ between the glutamate group and controls. P-Copeptin increased postoperatively with the highest values recorded on POD1 without significant inter-group differences. Among patients without diabetes, p-Copeptin did not differ preoperatively but postoperative rise from preoperative level to POD1 was significantly reduced in the glutamate group (73 ± 66 vs. 115 ± 102 pmol/L; p = .02). P-Copeptin was significantly lower in the Glutamate group on POD1 (p = .02) and POD 3 (p = .02).Conclusions
Glutamate did not reduce rises of p-Copeptin significantly after moderate to high-risk CABG. However, glutamate was associated with reduced rises of p-Copeptin among patients without diabetes. These results agree with previous observations suggesting that glutamate mitigates myocardial dysfunction after CABG in patients without diabetes. Given the exploratory nature of these findings, they need to be confirmed in future studies. 相似文献About 20–25% of patients experience weight regain (WR) or insufficient weight loss (IWL) after bariatric metabolic surgery (BS). Therefore, we aimed to retrospectively assess the effectiveness of adjunct treatment with the GLP-1 receptor agonist semaglutide in non-diabetic patients with WR or IWL after BS.
Materials and MethodsPost-bariatric patients without type 2 diabetes (T2D) with WR or IWL (n?=?44) were included in the analysis. The primary endpoint was weight loss 3 and 6 months after initiation of adjunct treatment. Secondary endpoints included change in BMI, HbA1c, lipid profile, hs-CRP, and liver enzymes.
ResultsPatients started semaglutide 64.7?±?47.6 months (mean?±?SD) after BS. At initiation of semaglutide, WR after post-bariatric weight nadir was 12.3?±?14.4% (mean?±?SD). Total weight loss during semaglutide treatment was???6.0?±?4.3% (mean?±?SD, p?<?0.001) after 3 months (3.2 months, IQR 3.0–3.5, n?=?38) and???10.3?±?5.5% (mean?±?SD, p?<?0.001) after 6 months (5.8 months, IQR 5.8–6.4, n?=?20). At 3 months, categorical weight loss was?>?5% in 61% of patients,?>?10% in 16% of patients, and?>?15% in 2% of patients. Triglycerides (OR?=?0.99; p?<?0.05), ALT (OR?=?0.87; p?=?0.05), and AST (OR?=?0.89; p?<?0.05) at baseline were negatively associated with weight loss of at least 5% at 3 months’ follow-up (p?<?0.05).
ConclusionTreatment options to manage post-bariatric excess weight (regain) are scarce. Our results imply a clear benefit of adjunct treatment with semaglutide in post-bariatric patients. However, these results need to be confirmed in a prospective randomized controlled trial to close the gap between lifestyle intervention and revision surgery in patients with IWL or WR after BS.
Graphical abstract 相似文献